title: HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells.
abstract: Drug resistance is the leading cause of chemotherapy failure in the treatment of ovarian cancer. So far, little is known about the mechanism of chemoresistance in ovarian cancer. In this study, we explored the mechanism that HSP27 was involved in cisplatin resistance of ovarian cancer both in vitro and clinically. HSP27 protein was found to be upregulated and expressed in cisplatin-resistant ovarian cancer cell line C13*, and HSP27 siRNA transfection reversed the chemoresistance of C13*. We found that HSP27 exerted its chemoresistant role by inhibiting p21 transferring from the nucleus to the plasma through the activation of phosphorylated-Akt pathway. These findings have implications for clinical trials aimed at a potential therapeutic target for ovarian tumors that are refractory to conventional treatment.
authors.affiliation: Cancer Biology Medical Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Lu
authors.forename: Chaoyang
authors.initials: C
authors.lastname: Sun
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.forename: Bo
authors.initials: B
authors.lastname: Zhou
authors.forename: Ensong
authors.initials: E
authors.lastname: Guo
authors.forename: Wanying
authors.initials: W
authors.lastname: Shan
authors.forename: Meng
authors.initials: M
authors.lastname: Xia
authors.forename: Kezhen
authors.initials: K
authors.lastname: Li
authors.forename: Danhui
authors.initials: D
authors.lastname: Weng
authors.forename: Li
authors.initials: L
authors.lastname: Meng
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Xu
authors.forename: Junbo
authors.initials: J
authors.lastname: Hu
authors.forename: Ding
authors.initials: D
authors.lastname: Ma
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002467:Cell Nucleus / Q000235:genetics / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage; D003593:Cytoplasm / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D055785:Gene Knockdown Techniques; D055551:HSP27 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D006360:Heat-Shock Proteins; D006801:Humans; D018832:Molecular Chaperones; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D054462:p21-Activated Kinases / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D055551:HSP27 Heat-Shock Proteins; C057725:HSPB1 protein, human; D006360:Heat-Shock Proteins; D018832:Molecular Chaperones; D034741:RNA, Small Interfering; D051057:Proto-Oncogene Proteins c-akt; D054462:p21-Activated Kinases; D002945:Cisplatin